The treatment of chronic venous disease is moving from the "off-label" use of arterial stents to highly engineered, vein-specific solutions. Valued at US$ 1.1 Billion in 2023, the Global Venous S...
In the delicate architecture of the urinary system, the ureteral stent is transitioning from a "necessary discomfort" to a high-tech, temporary resident. Valued at US$ 488.2 Million in 2022, the ...
